Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 12, 2013, Pages 1983-1992

  St Amour, Isabelle ^a,b,c   Paré, Isabelle ^c   Alata, Wael ^a,b   Coulombe, Katherine ^a,b,c   Ringuette Goulet, Cassandra ^a,b,c   Drouin Ouellet, Janelle ^d   Vandal, Milène ^a,b   Soulet, Denis ^a,e   Bazin, Renée ^b,c   Calon, Frédéric ^a,b  

^a Université Laval   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Centre de Recherche et Développement   (Canada)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

3xTg AD; Alzheimer's disease; Blood brain barrier; In situ cerebral perfusion; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN PERFUSION; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LIVER; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; MICE, INBRED C57BL;

EID: 84889089629     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.160     Document Type: Article

References (46)

1. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13. (Pubitemid 38569790)
2. Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 2005; 22: 1011-1037. (Pubitemid 41130789)
3. Johanson CE, Stopa EG, McMillan PN. The blood-cerebrospinal fluid barrier: structure and functional significance. Methods Mol Biol 2011; 686: 101-131.
4. Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011; 8: 7.
5. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012; 367: 2015-2025.
6. Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham-Rundles CH, Fireman P et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang 2003; 84: 202-210. (Pubitemid 36514177)
7. Fillit H, Hess G, Hill J, Bonnet P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73: 180-185.
8. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008; 30: 1728-1736.
9. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harbor Perspect Med 2012; 2: pii: a006239.
10. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010; 7: 90.
11. Jorgensen SH, Storm N, Jensen PEH, Laursen H, Sorensen PS. IVIg enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Exp Brain Res 2006; 178: 462-469.
12. St-Amour I, Bousquet M, Pare I, Drouin-Ouellet J, Cicchetti F, Bazin R et al. Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation 2012; 9: 234.
13. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421. (Pubitemid 36937044)
14. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675-688. (Pubitemid 40320703)
15. Bourasset F, Ouellet M, Tremblay C, Julien C, Do TM, Oddo S et al. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. Neuropharmacology 2009; 56: 808-813.
16. Hawkins BT, Egleton RD. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol 2008; 80: 277-309.
17. Leblanc P-P, Aiache J-M, Besner J-G, Buri P, Lesne M. Traite de Biopharmacie et Pharmacocinetique, 3rd edn. Les Presses de L'Universite de Montreal: Montreal, 1997, p 396.
18. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001; 114: 168-172. (Pubitemid 32184738)
19. Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG et al. Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol 2012; 238: 38-43.
20. Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T et al. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2009; 449: 240-245.
21. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24: 6144-6151. (Pubitemid 38891105)
22. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J 2006; 20: 2576-2578.
23. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919. (Pubitemid 30644751)
24. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002; 23: 2223-2226. (Pubitemid 36092057)
25. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther 2000; 292: 1048-1052. (Pubitemid 30136600)
26. Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH et al. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19: 1274-1282.
27. Zhao Q, Feng Y, Zhu Z, Dimitrov DS. Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity. Mol Cancer Ther 2011; 10: 1677-1685.
28. Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the guinea pig. Exp Neurol 1990; 107: 263-270. (Pubitemid 20085708)
29. Proulx DP, Rouleau P, Pare I, Vallieres-Noel MM, Bazin R. Interaction between intravenous immunoglobulin (IVIg) and the low-density lipoprotein receptorrelated protein 1: a role for transcytosis across the blood brain barrier? J Neuroimmunol 2012; 251: 39-44.
30. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25: 11495-11503. (Pubitemid 43102486)
31. Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F. in vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol 2011; 80: 32-39.
32. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011; 3: 84ra43.
33. Schroeder HWJ. Similarity and divergence in the development and expression of the mouse and human antibody repertoires. Dev Comp Immunol 2006; 30: 119-135.
34. Triguero D, Buciak JL, Pardridge WM. Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J Pharmacol Exp Ther 1991; 258: 186-192.
35. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood Blood 2012; 119: 5640-5649.
36. Sudduth TL, Greenstein A, Wilcock DM. Intracranial injection of gammagard, a human ivig, modulates the inflammatory response of the brain and lowers abeta in APP/PS1 mice along a different time course than anti-abeta antibodies. J Neurosci 2013; 33: 9684-9692.
37. Katsman Y, Foo AH, Leontyev D, Branch DR. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction. Transfusion 2010; 50: 1285-1294.
38. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10: 477-486. (Pubitemid 30216089)
39. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8: 226-234.
40. Wolak DJ, Thorne RG. Diffusion of macromolecules in the brain: implications for drug delivery. Mol Pharm 2013; 10: 1492-1504.
41. Wilcock D, Rojiani A, Rosenthal A, Subbarao S, Freeman M, Gordon M et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1: 24.
42. Balakrishnan K, Andrei-Selmer L-C, Selmer T, Bacher M, Dodel R. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis 2010; 20: 135-143.
43. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118: 103-113.
44. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging 2009; 30: 337-352.
45. Riches AC, Sharp JG, Thomas DB, Smith SV. Blood volume determination in the mouse. J Physiol 1973; 228: 279-284.
46. Kushida M, Kamendulis LM, Peat TJ, Klaunig JE. Dose-related induction of hepatic preneoplastic lesions by diethylnitrosamine in C57BL/6 mice. Toxicol Pathol 2011; 39: 776-786.